Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Lung Cancer Treatments and Mutations, and Cancer Genomics and Diagnostics.
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials
FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only, right-sided and/or <i>RAS</i> or <i>BRAF</i> mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials.
63P FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only (LL), right-sided and/or RAS or BRAF mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials
TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab
A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study
Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?
TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.
Prognostic significance of <i>K-Ras</i> mutation rate in metastatic colorectal cancer patients
Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients
Prognostic significance of <i>KRAS</i> mutation rate in metastatic colorectal cancer (mCRC) patients (pts).
Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.